By Fineline Cube 
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval from Brazil’s National Medical Products Administration (ANVISA) for its Talos straight tube thoracic aortic stent graft system. This approval follows the previous nod in Ecuador, marking another milestone in the company’s Latin American expansion.
Product Innovation
The Talos stent, recognized as the world’s first “breathable” covered stent, was approved for marketing in China in 2022. It is specifically designed for the surgical treatment of Stanford B-type aortic dissection. The stent’s unique distal perforation structure, with a selectable length ranging from 0 to 200mm, allows for the expansion of the distal true lumen of the thoracic aorta. This innovative design reduces the risk of spinal cord ischemia by minimizing excessive coverage of intercostal arteries, thereby enhancing long-term treatment effectiveness.
Clinical Benefits
The approval underscores the clinical benefits of Talos, which include improved distal true lumen remodeling and a reduced risk of complications associated with traditional stent grafts. This advancement positions MicroPort as a key player in the evolving landscape of vascular intervention solutions.-Fineline Info & Tech